文献
J-GLOBAL ID:201802287056264007
整理番号:18A1053083
日本における希少がんの治療開発の現状と改善のための提案
Current state of therapeutic development for rare cancers in Japan, and proposals for improvement
著者 (34件):
Kawai Akira
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Kawai Akira
(Department of Musculoskeletal Oncology and Rehabilitation, Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan)
,
Goto Toshio
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Goto Toshio
(Program for Drug Discovery and Medical Technology Platforms, RIKEN, Tsukuba, Japan)
,
Shibata Tatsuhiro
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Shibata Tatsuhiro
(Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan)
,
Tani Kenzaburo
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Tani Kenzaburo
(Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan)
,
Mizutani Shuki
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Mizutani Shuki
(Tokyo Medical and Dental University, Tokyo, Japan)
,
Nishikawa Akiyoshi
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Nishikawa Akiyoshi
(Biological Safety Research Center, National Institute of Health Sciences, Tokyo, Japan)
,
Shibata Taro
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Shibata Taro
(Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan)
,
Matsumoto Seiichi
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Matsumoto Seiichi
(Sarcoma Center, The Cancer Institute Hospital of JFCR, Tokyo, Japan)
,
Nagata Kyosuke
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Nagata Kyosuke
(University of Tsukuba, Tsukuba, Japan)
,
Narukawa Mamoru
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Narukawa Mamoru
(Department of Clinical Medicine (Pharmaceutical Medicine), School of Pharmacy, Kitasato University, Sagamihara, Japan)
,
Matsui Shigeyuki
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Matsui Shigeyuki
(Department of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan)
,
Ando Masashi
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Ando Masashi
(Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagakute, Japan)
,
Toguchida Junya
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Toguchida Junya
(Institute for Frontier Life and Medical Sciences/Center for iPS Cell Research and Application, Kyoto University, Tokyo, Japan)
,
Monden Morito
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Monden Morito
(Sakai City Hospital Organization, Sakai, Japan)
,
Heike Toshio
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Heike Toshio
(Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan)
,
Kimura Shinya
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Kimura Shinya
(Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan)
,
Ueda Ryuzo
(Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan)
,
Ueda Ryuzo
(Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute, Japan)
資料名:
Cancer Science (Web)
(Cancer Science (Web))
巻:
109
号:
5
ページ:
1731-1737
発行年:
2018年
JST資料番号:
U0505A
ISSN:
1349-7006
資料種別:
逐次刊行物 (A)
記事区分:
解説
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)